Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BROADWAY: Obicetrapib Added to Maximum Tolerated Lipid-Lowering Therapy in HeFH and/or ASCVD
jRCT2031220230Phase 3Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Aug 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia, heterozygous familial hypercholesterolemia (HeFH) and atherosclerotic disease comparing Obicetrapib 10 mg once daily with Placebo once daily (2 arms). Primary endpoint: LDL-C percent change at Day 84. Started Aug 2022; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemiaheterozygous familial hypercholesterolemia (HeFH)atherosclerotic disease
Beyond the preview
Go deeper on jRCT2031220230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220230.